American National Bank Buys 777 Shares of Bristol-Myers Squibb (NYSE:BMY)

American National Bank lifted its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 19.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,764 shares of the biopharmaceutical company’s stock after purchasing an additional 777 shares during the quarter. American National Bank’s holdings in Bristol-Myers Squibb were worth $343,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in BMY. Boston Partners boosted its position in shares of Bristol-Myers Squibb by 103.1% in the 3rd quarter. Boston Partners now owns 10,166,384 shares of the biopharmaceutical company’s stock worth $725,297,000 after purchasing an additional 5,161,226 shares in the last quarter. FMR LLC boosted its position in shares of Bristol-Myers Squibb by 7.2% in the 2nd quarter. FMR LLC now owns 71,882,436 shares of the biopharmaceutical company’s stock worth $5,534,947,000 after purchasing an additional 4,855,169 shares in the last quarter. BlackRock Inc. boosted its position in shares of Bristol-Myers Squibb by 2.0% in the 3rd quarter. BlackRock Inc. now owns 174,002,852 shares of the biopharmaceutical company’s stock worth $12,369,862,000 after purchasing an additional 3,357,590 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Bristol-Myers Squibb by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 199,886,585 shares of the biopharmaceutical company’s stock worth $14,209,937,000 after purchasing an additional 3,058,491 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Bristol-Myers Squibb by 131.2% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,307,254 shares of the biopharmaceutical company’s stock worth $408,659,000 after purchasing an additional 3,011,581 shares in the last quarter. 75.51% of the stock is owned by institutional investors.

Insider Transactions at Bristol-Myers Squibb

In related news, CEO Giovanni Caforio sold 240,000 shares of the company’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the transaction, the chief executive officer now owns 236,104 shares of the company’s stock, valued at approximately $17,625,163.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Giovanni Caforio sold 240,000 shares of the company’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the transaction, the chief executive officer now owns 236,104 shares of the company’s stock, valued at approximately $17,625,163.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Ann Powell sold 11,183 shares of the company’s stock in a transaction on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the completion of the transaction, the executive vice president now directly owns 23,043 shares of the company’s stock, valued at approximately $1,721,081.67. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday. They issued a “strong-buy” rating for the company. Jefferies Financial Group initiated coverage on shares of Bristol-Myers Squibb in a report on Monday, March 6th. They issued a “hold” rating and a $62.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Bristol-Myers Squibb in a report on Tuesday, January 17th. They issued an “overweight” rating and a $95.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “underweight” rating in a report on Friday, February 3rd. Finally, Atlantic Securities boosted their price objective on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, February 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $79.69.

Bristol-Myers Squibb Trading Down 0.8 %

NYSE:BMY opened at $66.53 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14. The firm has a market capitalization of $139.63 billion, a price-to-earnings ratio of 22.55, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46. Bristol-Myers Squibb has a one year low of $65.28 and a one year high of $81.43. The business has a fifty day moving average price of $70.96 and a 200-day moving average price of $72.88.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.71 by $0.11. The firm had revenue of $11.41 billion during the quarter, compared to analyst estimates of $11.20 billion. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. Bristol-Myers Squibb’s revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.83 EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 8.07 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Monday, April 10th will be paid a $0.57 dividend. The ex-dividend date is Thursday, April 6th. This represents a $2.28 annualized dividend and a dividend yield of 3.43%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 77.29%.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.